Almondz Global (ALMONDZ)
CyclicalScore breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹14.3 |
| Market Cap | ₹250.11 Cr |
| P/E Ratio | 7.49 |
| ROCE | 8.77% |
| ROE | 1.98% |
| Dividend Yield | 0% |
| Profit Growth | 70% |
| Debt/Equity | 0.17 |
| Sales Growth | 42.7% |
| Promoter Holding | 51.18% |
| 52-Week Range | ₹10.68 — ₹22.1 |
| Sector | Capital Markets |
| Book Value | ₹15.07 |
Strengths
- Low leverage: debt/equity of 0.19 and Piotroski F-Score of 7/9 indicate improving financial health
- Promoter holding of 51.18% aligns management with minority shareholders
- Strong recent momentum: sales up 56.33% and latest quarter net profit of ₹13 Cr on ₹52 Cr sales
- P/E of 9.63 and PEG of 0.04 look optically cheap if earnings growth is sustained
Concerns
- ROE is only 1.98%, showing weak return on book value despite the earnings spike
- Stockbroking is cyclical and commoditised; 409% profit growth is unlikely to be linear or durable
- No dividend yield means zero cash return while waiting for the story to play out
- P/B of 1.83 versus book value of ₹9.29 offers limited asset-based margin of safety
AI Analysis
At ₹16.99, Almondz Global trades at 9.63 times earnings, but I first ask what kind of business I am buying. This is a stockbroking firm, where competitive advantage is thin and revenues depend on market activity. The trailing numbers look exciting: sales grew 56.33%, profit jumped 409.05%, and the latest quarter delivered ₹52 Cr sales and ₹13 Cr net profit. A PEG ratio of 0.04 makes the growth look absurdly cheap—if it is durable. I doubt that. The return on equity is only 1.98%, so I am paying 1.83 times book value of ₹9.29 for a business earning less than 2% on that book. That is not Graham's margin of safety. The balance sheet is respectable: debt/equity is just 0.19, and the Piotroski F-Score of 7/9 suggests improving financial health. Promoter holding of 51.18% is reassuring. But there is zero dividend, so no cash yield while I wait. In broking, a 409% profit leap often signals a cyclical upswing, not permanent compounding. The 52-week range of ₹10.68–₹22.10 shows the volatility an investor must endure. The latest quarterly profit of ₹13 Cr is strong, but I need to know whether it is a new normal or a peak. I would not chase the stock at this price. I would keep it on my watchlist, watch the next few quarters, and wait for return on equity to rise sustainably. A low P/E in a cyclical business can be a value trap if earnings mean-revert. I prefer to buy when both balance-sheet strength and durable earning power are visible. Here, the numbers say improving; the business quality says caution.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer